APIM Therapeutics logo

APIM Therapeutics AS

APIM Therapeutics AS is using a series of proprietary Protein Protein Interaction (PPI) blocking peptides targeting complexes formed between PCNA (Proliferating Cell Nuclear Antigen) and proteins bearing a novel PCNA-interacting Peptide Motif called APIM (AlkB homolog 2 PCNA Interacting Motif). A series of preclinical and other experiments have revealed the functional importance of PCNA/APIM-protein interactions in the regulation of cancer cell growth and apoptosis e.g. during DNA Damage Response (DDR) induced by anti-cancer treatment. Furthermore, it was shown that cell penetrating peptides containing the APIM-motif abrogate PCNA-APIM protein interactions and are capable of potentiating the action of several classes of anti-cancer drugs across multiple indications.

KEY DETAILS

Websitehttps://www.apimtherapeutics.com
Founded
Disease Focus
Development Stage
STOCK CODENon Listed
Address
c/o NTNU Technology Transfer AS Sem S¥landsvei 14 Kjemiblokk 1, 3etg 7491
Trondheim
Norway
Email
Contact Number
+47 73 49 4002